Valiant Laboratories

Valiant Laboratories Debt Growth

The Year-over-Year Debt Growth of Valiant Laboratories (VALIANTLAB.NS) as of Nov 4, 2026 is -62.02 %. In the previous year, Year-over-Year Debt Growth was 58.64 % — a change of -205.78% (lower).

Debt Growth

-62.02 %

YoY

-205.78%

Last updated:

Year-over-Year Debt Growth of Valiant Laboratories is 2026 -62.02 % . Year-over-Year Debt Growth of Valiant Laboratories was 2025 58.64 % . It decreases by -205.78% lower compared to the previous year.

The Valiant Laboratories Debt Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt Growth
Date
Debt Growth
Jan 1, 2022
10,020.20 INR
Jan 1, 2023
-1.49 INR
Jan 1, 2024
27.39 INR
Jan 1, 2025
58.64 INR
Jan 1, 2026
-62.02 INR
The Valiant Laboratories Debt Growth history
YEARDebt GrowthYoY
-62.02 %-205.78%
58.64 %+114.10%
27.39 %-1,941.62%
-1.49 %-100.01%
10,020.20 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valiant Laboratories Stock analysis

What does Valiant Laboratories do? Valiant Laboratories Ltd manufactures paracetamol API/bulk drug for pharmaceutical applications, targeting medical conditions such as headache, muscle ache, arthritis, back ache, toothache, cold, and fever. The company operates a single manufacturing facility at Tarapur industrial estate, approximately 150 km from Nhava Sheva Port (JNPT), producing specialty chemicals and pharma intermediates for domestic and international markets. Its subsidiary, VALIANT ADVANCED SCIENCES PRIVATE LIMITED, supports the company's operations in the pharmaceutical sector. The firm's primary revenue comes from selling paracetamol API and specialty chemicals to pharmaceutical companies and distributors globally. Manufacturing focuses on high-demand applications like pain relief and fever treatment, with products distributed across India and abroad. The company leverages its Tarapur facility's proximity to Nhava Sheva Port for efficient export logistics. Valiant Laboratories Ltd serves the pharmaceutical industry by supplying essential active ingredients, particularly paracetamol, which is widely used in over-the-counter medications. The company's manufacturing capabilities for specialty chemicals and pharma intermediates cater to both domestic and international clients seeking reliable API sources. Its single-location production model ensures focused resource allocation for consistent output quality. Valiant Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Valiant Laboratories stock

Year-over-Year Debt Growth of Valiant Laboratories is -62.02 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year Debt Growth Valiant Laboratories since 2006 – with annual values, charts, and detailed analysis.

Debt growth measures the percentage change in total debt. Rising debt growth should be compared with revenue and earnings growth to assess sustainability.

To evaluate Year-over-Year Debt Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Debt Growth.

Year-over-Year Debt Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Debt Growth's Valiant Laboratories historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Valiant Laboratories

All Key Metrics — Valiant Laboratories